Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Clinical presentation and management of Mixed-Phenotype Acute leukemia (MPAL) is heterogeneous. This descriptive observationnal study aims to review MPAL cases in the East of France based on a 10-year multicentre retrospective collection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Age of the patients when diagnosed with MPAL | Age in years | At inclusion (Day 0) |
| Sex of the patients when diagnosed with MPAL | Male or female | At inclusion (Day 0) |
| City of the hematology unit in charge of each patient for the treatment of MPAL | Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon or Besançon | At inclusion (Day 0) |
| MPAL rate in the each hematology unit | Rate of MPAL out of the total number of patients diagnosed with acute leukemia in each hematology unit | 10 years (01/01/2008-01/01/2018) |
| Date of MPAL diagnosis for each patient | At inclusion (Day 0) | |
| Type of MPAL for each patient | De novo MPAL or secondary to myelodysplasia MPAL | At inclusion (Day 0) |
| Percentage of blood blasts for each patient at diagnosis of MPAL | On the first blood sample analyzed | At inclusion (D0) |
| Percentage of medullar blasts for each patient at diagnosis of MPAL | On the first bone marrow sample analyzed | At inclusion (Day 0) |
| Measure | Description | Time Frame |
|---|---|---|
| Date of every relapse for each patient | 10 years (01/01/2008-01/01/2018) | |
| Date of death if occured | 10 years (01/01/2008-01/01/2018) | |
| Cause of death |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Adult patients from one of the following 7 hospitals : Nancy, Metz-Thionville, Reims, Strasbourg, Mulhouse, Dijon, Besançon
Not provided
| ID | Term |
|---|---|
| D015456 | Leukemia, Biphenotypic, Acute |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Cytologic characteristics: type of myeloid markers at diagnosis for each patient | Presence or not of myeloid markers generally sought in the diagnosis of acute leukaemias | At inclusion (Day 0) |
| Cytologic characteristics: type of B lymphoid markers at diagnosis for each patient | Presence or not of B lymphoid markers generally sought in the diagnosis of acute leukaemias | At inclusion (Day 0) |
| Cytologic characteristics: type of T lymphoid markers | Presence or not of T lymphoid markers generally sought in the diagnosis of acute leukemias | At inclusion (D0) |
| Medullar MPO positivity percentage at diagnosis for each patient | If performed on the bone marrow sample used to confirm the diagnosis | At inclusion (Day 0) |
| Genetic characteristics on the caryotype at diagnosis for each patient | Presence or not of caryotypic abnormalities generally sought in the diagnosis of acute leukemias | At inclusion (Day 0) |
| Genetic characteristics on molecular biology analysis at diagnosis for each patient | Presence or not of molecular biology abnormalities generally sought in the diagnosis of acute leukemias | At inclusion (D0) |
| Classification of biphenotypic acute leukemia (BAL) according to the EGIL 1998 criterias at diagnosis | BAL or not | At inclusion (Day 0) |
| Classification of MPAL according to the WHO 2008 criterias at diagnosis | MPAL or not | At inclusion (Day 0) |
| Type of treatments and dates of the first day of every treatment line for each patient | Myeloid or lymphoid chemotherapy regimen | 10 years (01/01/2008-01/01/2018) |
| Medullar response for every treatments line for each patient | Complete cytological and molecular response or treatment failure | 10 years (01/01/2008-01/01/2018) |
| Treatment including allogenic hematopoietic stem cells transplant (HSCT) (yes or no) with type of conditionning regimen for each patient | High-dose, reduced-intensity or nonmyeloablative conditioning regimens with or without total body irradiation | 10 years (01/01/2008-01/01/2018) |
| HSCT complicated with acute and/or chronic graft-versus-host disease with severity grade and treatments for each patient | Diagnosis of GVHD according to Filipovich criterias (BMT 2005); Severity grade according to Seattle criterias; Type of treatments: steroids, other immunosuppressive agents, extracorporeal photopheresis | 10 years (01/01/2008-01/01/2018) |
Secondary to leukemia, treatment or other cause |
| 10 years (01/01/2008-01/01/2018) |
| D006402 |
| Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |